AOD-9604 in Ficheux — Fat Loss Peptide Research Guide
AOD-9604 research guide for Ficheux. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 isn't stocked on pharmacy shelves in Ficheux or virtually any local market — it's a research-grade peptide available through a dedicated online market. This matters because AOD-9604 quality ranges widely across the market — from pharmaceutical-grade 99%+ purity to products with serious contamination — and the vendor determines everything about the product. Separating properly characterised AOD-9604 from the rest of the market requires three things: an HPLC chromatogram documenting ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. Use this guide to verify vendor quality systematically — the framework here work regardless of your location.
Understanding AOD-9604 — Biology & Evidence
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Ficheux studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Where to Buy AOD-9604 — A Researcher's Guide
The most consistent path to quality AOD-9604 is community research first — peptide forums aggregate real purchasing experience that are more trustworthy than marketing materials. Mass spectrometry in the COA verifies that the main HPLC peak is actually AOD-9604 and not another compound with similar chromatographic behaviour — HPLC purity alone provides no identity confirmation. For Ficheux researchers evaluating new suppliers: a modest first purchase to test the product before placing larger orders is standard practice in the community. For Ficheux researchers making a first AOD-9604 purchase: work through this evaluation framework first, begin with a small order, and verify batch traceability on arrival before use.
Order AOD-9604 — ships to Ficheux
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and limited human studies. Reconstitute AOD-9604 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg vial with 2mL bac water yields 2.5mg/mL — providing 25mcg per unit measured on a 100-unit syringe. The primary quality-related safety risk in AOD-9604 research is endotoxin contamination from poor sourcing — a verified endotoxin panel in the batch COA is the direct mitigation for this hazard. Researchers running multi-compound protocols with AOD-9604 should examine published studies for potential interaction data before proceeding with any multi-compound protocol.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
